Role of atazanavir in the treatment of HIV infection.
PMID: 19436623
2009
Therapeutics and clinical risk management
Introduction: Mutations more significant to be included in the GIQ model are the following: L10F/I/V, K20M/R, L24I, D30N, V32I, L33F, M36I/L, I47V/A, G48V, I50V, I50L, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73S, V77I, V82A/F/T, I84V, N88D/S and
Molecular epidemiology of HIV-1 in St Petersburg, Russia: predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters.
PMID: 19363451
2009
Journal of acquired immune deficiency syndromes (1999)
Abstract: A second subcluster (17.4% AFSU viruses) corresponds to the variant with the V77I substitution in protease, which is widely circulating in different FSU countries.
Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure.
PMID: 18992847
2009
Infection, genetics and evolution
Abstract: In untreated patients, mutations L10V, K20R, and M36I were more frequent in subtype F1, while L63P, A71T, and V77I were more prevalent in subtype B.
Method: Mutations L10F/I/R/V, K20M/R, L24I, L33F, M36I, F53L, I54V/L/A/M/T/S, L63P, A71V/T, G73C/S/T/A, V77I and N88D/S were considered as minor resist
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
PMID: 18390885
2008
The Journal of antimicrobial chemotherapy
Abstract: Two fosamprenavir/ritonavir mutation scores were constructed: score A (L10F/I/V + L33F + M36I + I54L/M/V/A/T/S + I62V + V82A/F/C/G + I84V + L90M) was based only on mutations associated with a worse VR, whereas score B (L10FIV + L33F + M36I + I54L/M/V/A/T/S + A71V - V77I - N88S + L90M) also took into account favourable mutations.
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
PMID: 18212102
2008
Antimicrobial agents and chemotherapy
Abstract: During in vitro selection, A-790742 selected two primary mutations (V82L and I84V) along with L23I, L33F, K45I, A71V/A, and V77I in the pNL4-3 background and two other mutations (A71V and V82G) accompanied by M46I and L63P in the HIV-1 RF background.
Conformational flexibility in the flap domains of ligand-free HIV protease.
Abstract: The mutant HIV PR, which evolved in response to treatment with the potent inhibitor TL-3, contains six point mutations relative to the wild-type enzyme (L24I, M46I, F53L, L63P, V77I, V82A).
Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Abstract: The proportion of substitutions L63P, A71T/V, V77I and I93L in subtype B' sequences was considerably higher than in CRF01_AE viruses, while the proportion of L10I, M36I and K20R/I substitutions in subtype B' sequences was relatively lower than in CRF01_AE strains.
Study of drug resistance among 78 antiretroviral treatment-naive patients with HIV-1 subtype B infection in central China.
PMID: 22504392
2007
Drug discoveries & therapeutics
Abstract: The most common mutations were L63P, V77I and I93L, which belong to minor mutations of the proteinase gene, and none of which had any relation to viral loads.
Genetic characterization of HIV-1 strains circulating in Kazakhstan.
PMID: 17514018
2007
Journal of acquired immune deficiency syndromes (1999)
1Abstract: In addition, most had the other 2 mutations that characterize the ""V77I haplotype."" All 6 nearly full-length sequences were subtype A and clustered with other FSU strains."
Abstract: From these sequences, 47 (58.8%) presented the secondary protease inhibitor mutation V77I that has been linked to a genetic lineage in the FSU epidemic.
Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference.
PMID: 17411368
2007
AIDS research and human retroviruses
Abstract: The frequencies of minor mutations to protease inhibitors (PI) were I93L (71.4%), L63P (62.6%), V77I (62.6%), M36I/V (33.0%), A71T/V (22.0%), K20R (6.6%), G16E (6.6%), and L10I (5.5%).
HIV mutation literature information.
PMID: 
2009
Therapeutics and clinical risk management
Browser Board
Co-occurred Entities
Filtrator
ViMRT